Key facts
- Mend (Pharmaceuticals and Biotechnology)’s last known valuation is $115.0M (Feb 2026).
- It has raised $36.2M; the latest was Later Stage VC ($13.8M) in Feb 2026.
- Notable investors include Alumni Ventures, S2G Investments, iSelect Fund, The Pay It Forward Company, H/L Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Mend (Pharmaceuticals and Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Mend (Pharmaceuticals and Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mend (Pharmaceuticals and Biotechnology)
Developer of clinical nutritional products designed to assist people in healing and living a quality life. The company is focused on researching and developing clinical nutrition and medical food interventions to enhance patient outcomes and is in constant research and development, enabling caregivers to construct useful health outcomes from injury, surgery, or illness for aging and human performance purposes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 47
- Website
- mend.me/
- Ownership
- Privately Held (backing)
Mend (Pharmaceuticals and Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mend (Pharmaceuticals and Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mend (Pharmaceuticals and Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.